Clinical Trial Update: Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating pazopanib with or without pembrolizumab for metastatic soft tissue sarcoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Votrient (Pazopanib)

Snippet

Sponsor: Yonsei University | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: RECRUITING